TY - JOUR
AU - Stojković, Miodrag
AB - The New Year is always an opportunity to reflect on our achievements as well as to look forward with renewed vigor. The stem cell field has seen many exciting achievements, some of them most prominent, the improvement of induced pluripotency stem cell (iPSC) technology. As Stem Cells has consistently done throughout its 27-year history, it continues to foster the evidence-based development of the stem cell field by publishing significant manuscripts of lasting and high impact. The popularity of Stem Cells is confirmed by the ongoing impressive submission rate of new manuscripts. In 2009, the editorial board had the pleasure and privilege of reading more than 1,400 new manuscripts, reflecting a continuous commitment of authors to publish in Stem Cells. In 2008, the average time from submission to first decision was 22.6 days. This past year we are pleased to have reduced this to 14 days, which confirms our goal to help authors publish their most recent findings as expeditiously as possible. As we reduced our evaluation time, we continued to place a high value on the importance of the critical screening of manuscripts, especially photomicrographs, keeping in mind that scientific fraud has a detrimental effect on the whole field. The goal of Stem Cells is not to control scientific research and results; our goal is simply to disseminate the best scientific content. In 2009, we published 274 accepted manuscripts within the 12 monthly issues of the journal. We were pleased to share many new and exciting conclusions with scientists, clinicians, law makers, politicians, ethicists, and laypersons within the different journal sections covering iPSC, embryonic stem cells, tissue specific stem cells, epigenetics, genomics, proteomics and metabonomics, the stem cell niche, translational and clinical research, and, finally, the regenerative medicine that we launched at the end of the third quarter. This section focuses on the unique characteristics of stem cells being developed for major new medical and therapeutic applications with the long-term goal of better care for patients with debilitating human diseases. Stem Cells also continues its proud promotion of young scientists through its Young Investigation Award (YIA). This year, the fifth Stem Cells YIA will be held at the eighth International Stem Cell Symposium in Seoul, Korea. This $10,000 award is not only one of the most prestigious among the scientific community but also is an acknowledgment of the effort and dedication of young scientists in the formative years of their careers, culminating in the publication of their work by the journal. The many achievements of the past year would not have been possible without the partnership of many people, in particular, our editorial board members who served as lead reviewers, our external reviewers and, of course, our authors. To all of them, we express our gratitude for their invaluable service, hard work, and dedication. They have helped us maintain the highest scientific standards for our and your journal, Stem Cells. So it is we reflect on a very successful year past and now we look forward to 2010, the journal's 28th year of publication with a renewal of its original commitment, of “scientists in the service of science.” Disclosure of Potential Conflicts of Interest The authors indicate no potential conflicts of interest. Author notes Disclosure of potential conflicts of interest is found at the end of this article. First published online in STEM CELLS EXPRESS December 21, 2009. Copyright © 2009 AlphaMed Press This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - Stem Cells Continues to Perform and Flourish
JF - Stem Cells
DO - 10.1002/stem.287
DA - 2010-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/stem-cells-continues-to-perform-and-flourish-NpBShO6FlE
SP - 1
EP - 1
VL - 28
IS - 1
DP - DeepDyve
ER -